TD Asset Management Inc Grows Position in Immatics N.V. $IMTX

TD Asset Management Inc grew its stake in shares of Immatics N.V. (NASDAQ:IMTX) by 33.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 383,804 shares of the company’s stock after buying an additional 95,548 shares during the period. TD Asset Management Inc’s holdings in Immatics were worth $3,270,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of IMTX. Sofinnova Investments Inc. raised its position in shares of Immatics by 44.1% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock valued at $12,054,000 after purchasing an additional 686,224 shares during the period. Aberdeen Group plc raised its holdings in Immatics by 9.7% during the third quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock valued at $6,726,000 after acquiring an additional 69,860 shares during the period. Wasatch Advisors LP lifted its position in shares of Immatics by 35.9% in the second quarter. Wasatch Advisors LP now owns 785,154 shares of the company’s stock valued at $4,224,000 after acquiring an additional 207,491 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Immatics by 31.5% in the second quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock valued at $1,069,000 after acquiring an additional 47,590 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Immatics by 105.2% in the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock worth $420,000 after acquiring an additional 40,058 shares during the period. 64.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IMTX. Leerink Partners reissued an “outperform” rating and set a $17.00 target price on shares of Immatics in a research note on Thursday, December 4th. Guggenheim increased their price objective on shares of Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Mizuho set a $25.00 price target on Immatics in a research note on Thursday, February 19th. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.20.

Immatics Stock Performance

NASDAQ:IMTX opened at $10.18 on Thursday. The firm has a market capitalization of $1.24 billion, a PE ratio of -9.98 and a beta of 1.34. The stock’s fifty day moving average is $9.90 and its 200 day moving average is $9.13. Immatics N.V. has a fifty-two week low of $3.30 and a fifty-two week high of $12.41.

Immatics Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.